<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83836">
  <stage>Registered</stage>
  <submitdate>21/04/2009</submitdate>
  <approvaldate>5/05/2009</approvaldate>
  <actrnumber>ACTRN12609000226202</actrnumber>
  <trial_identification>
    <studytitle>Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of neuroendocrine tumours.</studytitle>
    <scientifictitle>An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A-9B-52030-220. Ipsen Pty Ltd</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuroendocrine Tumours</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Somatuline Autogel for neuroendocrine tumours. This will be administered subcutaneously at a dose and frequency clinically indicated. The dose and frequency for Somatuline Autogel will vary for participants depending on the physicians discretion. The duration of the observation will be up to 4 years. Both the health care professional group and home injection group will be exposed to the therapy. The home injection group will inject themselves or have a partner/carer inject.</interventions>
    <comparator>Health Care Professional injection will be the comparator group. These patients will be injected with Somatuline Autogel by a health care professional.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and Local Tolerability of Somatuline Autogel assessed by question to the patient on the incidence of untoward effects. This will be recorded in an electronic case report form (eCRF).</outcome>
      <timepoint>The primary assessment question will be asked prior to each administration of Somatuline Autogel over the 4 year period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of Somatuline Autogel measured by the completion of survey (eCRF) by treating physician.</outcome>
      <timepoint>Assessed prior to each administration of Somatuline Autogel over the 4 year period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Home Injection Training Requirements measured by the completion of survey (eCRF) by treating physician.</outcome>
      <timepoint>Assessed prior to each administration of Somatuline Autogel over the 4 year period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acceptability of Home Injection measured by the completion of survey (eCRF) by treating physician.</outcome>
      <timepoint>Assessed prior to each administration of Somatuline Autogel over the 4 year period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients on a stable dose of Somatuline Autogel for at least 4 months and with a diagnosis of Neuroendocrine tumours.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who are pregnant or breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Random sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/08/2009</anticipatedstartdate>
    <actualstartdate>5/08/2009</actualstartdate>
    <anticipatedenddate>5/08/2011</anticipatedenddate>
    <actualenddate>22/08/2011</actualenddate>
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2430</postcode>
    <postcode>2348</postcode>
    <postcode>2310</postcode>
    <postcode>2291</postcode>
    <postcode>2077</postcode>
    <postcode>2217</postcode>
    <postcode>2065</postcode>
    <postcode>5000</postcode>
    <postcode>6008</postcode>
    <postcode>6005</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, Victoria, Australia 3150. </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ipsen Pty Ltd</fundingname>
      <fundingaddress>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, Victoria, Australia 3150. </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will compare the safety and tolerability of a treatment for neuroendocrine tumours in two groups: one group is injected by a health care professional the other group will inject themselves or have a carer/partner inject.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Reseach Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1
New Lambton  NSW  2305</ethicaddress>
      <ethicapprovaldate>27/04/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>28/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Monica de Abadal</name>
      <address>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, Victoria, Australia, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax>+61 3 9562 5152</fax>
      <email>monica.deabadal@ipsen.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Jay Dharma</name>
      <address>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, Victoria, Australia, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax>+61 3 9562 5152</fax>
      <email>jay.dharma@ipsen.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jay Dharma</name>
      <address>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, Victoria, Australia, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax>+61 3 9562 5152</fax>
      <email>jay.dharma@ipsen.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Tony Bonaventura</name>
      <address>Department of Medical Oncology
Newcastle Private Hospital
14 Lookout Road (PO Box 466)
New Lambton Heights, NSW, 2305
</address>
      <phone>+61 2 4941 8424</phone>
      <fax />
      <email>Tony.Bonaventura@mater.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>